To evaluate the cardiovascular risks associated with allopurinol use in gout patients, specifically focusing on the incidence of ischaemic events and the modifying effect of colchicine therapy.
Key Findings:
Highest incidence rate ratio (IRR) for ischaemic cardiovascular events during the first 30 days after allopurinol initiation (IRR 1.51, 95% CI 1.29–1.77).
Risk significantly increased for doses >300 mg (IRR 3.92, 95% CI 2.73–5.63) compared to <300 mg (IRR 1.69, 95% CI 1.31–2.18).
Concomitant colchicine use mitigated early cardiovascular risk, with IRR for low-dose allopurinol plus colchicine at 1.02 (95% CI 0.78–1.32).
Interpretation:
Cardiovascular risk in gout patients is influenced by urate-lowering therapy, particularly high doses of allopurinol at initiation, but can be reduced with colchicine, which appears to neutralize the early risk.
Limitations:
Pre-existing atherosclerotic cardiovascular disease was not reported, which may affect the generalizability of the findings.
Use of antiplatelet prescriptions as a proxy for cardiovascular events may introduce misclassification, potentially skewing results.
Conclusion:
The study highlights the dynamic relationship between allopurinol use, gout, and cardiovascular risk, emphasizing the importance of dose and concomitant therapy, which may inform clinical decision-making.
The nurse practitioner profession claims the No. 1 spot across three categories in the U.S. News & World Report 2026 Best Jobs rankings for the third consecutive year.
